Champions Oncology (CSBR) said Wednesday that it signed a licensing agreement with Weill Cornell Medicine, allowing it to distribute and commercialize the latter's hematological patient-derived xenograft models.
Under the deal, Champions Oncology will have exclusive rights to offer services that use Weill Cornell Medicine's xenograft models for a limited time, according to the statement. The company said it will also serve as a repository for the models' distribution to academic institutions globally.
No financial details were disclosed.
Price: 4.45, Change: -0.09, Percent Change: -1.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments